vs
Evercore Inc.（EVR）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是Evercore Inc.的1.2倍（$1.5B vs $1.3B），Evercore Inc.净利率更高（15.7% vs 12.9%，领先2.8%），Evercore Inc.同比增速更快（32.4% vs 9.2%），Evercore Inc.自由现金流更多（$798.6M vs $199.5M），过去两年Evercore Inc.的营收复合增速更高（48.9% vs 15.8%）
Evercore Inc.（前称Evercore Partners）是1995年由罗杰·奥尔特曼、大卫·奥芬森德、奥斯汀·博伊特纳联合创立的全球独立投资银行咨询机构。成立至今，公司已为总规模超4.7万亿美元的并购、重组交易提供专业咨询服务，在全球投行业务领域拥有较高声誉。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
EVR vs STE — 直观对比
营收规模更大
STE
是对方的1.2倍
$1.3B
营收增速更快
EVR
高出23.2%
9.2%
净利率更高
EVR
高出2.8%
12.9%
自由现金流更多
EVR
多$599.1M
$199.5M
两年增速更快
EVR
近两年复合增速
15.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.5B |
| 净利润 | $204.0M | $192.9M |
| 毛利率 | — | 43.8% |
| 营业利润率 | 24.2% | 18.3% |
| 净利率 | 15.7% | 12.9% |
| 营收同比 | 32.4% | 9.2% |
| 净利润同比 | 45.2% | 11.2% |
| 每股收益（稀释后） | $4.80 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVRSTE
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.0B | $1.5B | ||
| Q2 25 | $838.0M | $1.4B | ||
| Q1 25 | $699.0M | $1.5B | ||
| Q4 24 | $979.5M | $1.4B | ||
| Q3 24 | $738.4M | $1.3B | ||
| Q2 24 | $693.4M | $1.3B | ||
| Q1 24 | $585.0M | $1.1B |
净利润EVRSTE
| Q4 25 | $204.0M | $192.9M | ||
| Q3 25 | $144.6M | $191.9M | ||
| Q2 25 | $97.2M | $177.4M | ||
| Q1 25 | $146.2M | $145.7M | ||
| Q4 24 | $140.4M | $173.5M | ||
| Q3 24 | $78.4M | $150.0M | ||
| Q2 24 | $73.8M | $145.4M | ||
| Q1 24 | $85.7M | $-1.4M |
毛利率EVRSTE
| Q4 25 | — | 43.8% | ||
| Q3 25 | — | 44.2% | ||
| Q2 25 | — | 45.1% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 43.6% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | — | 40.2% |
营业利润率EVRSTE
| Q4 25 | 24.2% | 18.3% | ||
| Q3 25 | 20.8% | 18.2% | ||
| Q2 25 | 18.0% | 17.7% | ||
| Q1 25 | 16.0% | 14.6% | ||
| Q4 24 | 21.8% | 17.9% | ||
| Q3 24 | 16.7% | 16.5% | ||
| Q2 24 | 15.9% | 14.5% | ||
| Q1 24 | 14.8% | 22.0% |
净利率EVRSTE
| Q4 25 | 15.7% | 12.9% | ||
| Q3 25 | 13.8% | 13.1% | ||
| Q2 25 | 11.6% | 12.8% | ||
| Q1 25 | 20.9% | 9.8% | ||
| Q4 24 | 14.3% | 12.7% | ||
| Q3 24 | 10.6% | 11.3% | ||
| Q2 24 | 10.6% | 11.4% | ||
| Q1 24 | 14.6% | -0.1% |
每股收益（稀释后）EVRSTE
| Q4 25 | $4.80 | $1.96 | ||
| Q3 25 | $3.41 | $1.94 | ||
| Q2 25 | $2.36 | $1.79 | ||
| Q1 25 | $3.48 | $1.48 | ||
| Q4 24 | $3.32 | $1.75 | ||
| Q3 24 | $1.86 | $1.51 | ||
| Q2 24 | $1.81 | $1.46 | ||
| Q1 24 | $2.09 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0B | $423.7M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | $2.0B | $7.2B |
| 总资产 | $5.4B | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资EVRSTE
| Q4 25 | $3.0B | $423.7M | ||
| Q3 25 | $2.4B | $319.2M | ||
| Q2 25 | $1.7B | $279.7M | ||
| Q1 25 | $1.4B | $171.7M | ||
| Q4 24 | $2.4B | $155.2M | ||
| Q3 24 | $1.8B | $172.2M | ||
| Q2 24 | $1.7B | $198.3M | ||
| Q1 24 | $1.4B | $207.0M |
总债务EVRSTE
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $3.1B |
股东权益EVRSTE
| Q4 25 | $2.0B | $7.2B | ||
| Q3 25 | $1.8B | $7.0B | ||
| Q2 25 | $1.7B | $7.0B | ||
| Q1 25 | $1.5B | $6.6B | ||
| Q4 24 | $1.7B | $6.4B | ||
| Q3 24 | $1.6B | $6.6B | ||
| Q2 24 | $1.5B | $6.4B | ||
| Q1 24 | $1.4B | $6.3B |
总资产EVRSTE
| Q4 25 | $5.4B | $10.6B | ||
| Q3 25 | $4.4B | $10.4B | ||
| Q2 25 | $3.7B | $10.4B | ||
| Q1 25 | $3.3B | $10.1B | ||
| Q4 24 | $4.2B | $10.0B | ||
| Q3 24 | $3.6B | $10.2B | ||
| Q2 24 | $3.3B | $10.1B | ||
| Q1 24 | $3.0B | $11.1B |
负债/权益比EVRSTE
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $807.5M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $798.6M | $199.5M |
| 自由现金流率自由现金流/营收 | 61.6% | 13.3% |
| 资本支出强度资本支出/营收 | 0.7% | 6.6% |
| 现金转化率经营现金流/净利润 | 3.96× | 1.55× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $917.1M |
8季度趋势，按日历期对齐
经营现金流EVRSTE
| Q4 25 | $807.5M | $298.2M | ||
| Q3 25 | $560.9M | $287.8M | ||
| Q2 25 | $437.7M | $420.0M | ||
| Q1 25 | $-549.7M | $260.8M | ||
| Q4 24 | $686.4M | $332.8M | ||
| Q3 24 | $234.5M | $250.7M | ||
| Q2 24 | $348.5M | $303.7M | ||
| Q1 24 | $-281.2M | $254.8M |
自由现金流EVRSTE
| Q4 25 | $798.6M | $199.5M | ||
| Q3 25 | $541.5M | $201.3M | ||
| Q2 25 | $411.7M | $326.4M | ||
| Q1 25 | $-569.3M | $189.9M | ||
| Q4 24 | $673.1M | $243.6M | ||
| Q3 24 | $226.6M | $148.8M | ||
| Q2 24 | $340.7M | $195.7M | ||
| Q1 24 | $-282.3M | $163.3M |
自由现金流率EVRSTE
| Q4 25 | 61.6% | 13.3% | ||
| Q3 25 | 51.8% | 13.8% | ||
| Q2 25 | 49.1% | 23.5% | ||
| Q1 25 | -81.4% | 12.8% | ||
| Q4 24 | 68.7% | 17.8% | ||
| Q3 24 | 30.7% | 11.2% | ||
| Q2 24 | 49.1% | 15.3% | ||
| Q1 24 | -48.3% | 14.6% |
资本支出强度EVRSTE
| Q4 25 | 0.7% | 6.6% | ||
| Q3 25 | 1.9% | 5.9% | ||
| Q2 25 | 3.1% | 6.7% | ||
| Q1 25 | 2.8% | 4.8% | ||
| Q4 24 | 1.4% | 6.5% | ||
| Q3 24 | 1.1% | 7.7% | ||
| Q2 24 | 1.1% | 8.4% | ||
| Q1 24 | 0.2% | 8.2% |
现金转化率EVRSTE
| Q4 25 | 3.96× | 1.55× | ||
| Q3 25 | 3.88× | 1.50× | ||
| Q2 25 | 4.50× | 2.37× | ||
| Q1 25 | -3.76× | 1.79× | ||
| Q4 24 | 4.89× | 1.92× | ||
| Q3 24 | 2.99× | 1.67× | ||
| Q2 24 | 4.72× | 2.09× | ||
| Q1 24 | -3.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVR
| Advisory Fees | $1.1B | 87% |
| Commissions And Related Revenue | $66.5M | 5% |
| Underwriting Fees | $49.5M | 4% |
| Other | $29.6M | 2% |
| Investment Management | $23.2M | 2% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
